CBD Does Not Help Migraine. THC Plus CBD Might.

Picture the two pains that quietly ruin more days than almost anything else on earth. One is the dull ache in your lower back that makes it hard to get out of a chair and hard to sleep. The other is the migraine that arrives like a storm, dims the light, turns your stomach, and steals a full day.

People reach for CBD for both. It feels gentle, it is widely legal, and the internet is full of voices saying it fixes pain. So here is the honest version. The story is narrower than the hype, but for the first time it is genuinely actionable, because some cannabis helps some of these pains and some does not.

Why These Two Conditions Are the Right Test Cases

These are not random choices for a cannabis review. They are the two pain conditions where the research has matured enough to say something useful, and both are among the heaviest burdens on human health.

For migraine alone, the numbers are staggering. About 40 million people in the United States and roughly 1.1 billion worldwide live with migraine. It ranks as the second leading cause of disability-adjusted life years globally, and it is the single top cause of years lived with disability among women aged 15 to 49. People with migraine lose about 3.51 hours of productive time every week.

Low back pain sits right beside it as a global heavyweight, a top contributor to years lived with disability across most countries. Both are common, chronic, and stubborn, which is why the evidence here is worth reading closely.

The Big Picture First: What the 2026 Systematic Review Found

Start with the widest lens, because it keeps everything else in proportion. A 2026 systematic review in Cannabis and Cannabinoid Research looked at randomized controlled trials of cannabinoid-based interventions for low back pain and migraine. It found 5 trials covering 1,072 participants, the best snapshot of the field.

Its verdict is blunt and useful. There is no class-wide effect. You cannot say "cannabis helps pain" as a blanket statement. Whether a product works depends on the indication, the formulation, the route, and the exact mix of cannabinoids.

The review broke the picture into pieces. A single 400 mg oral dose of CBD was not superior to placebo for acute low back pain. For acute migraine, there was moderate-certainty evidence that vaporized THC plus CBD helps, giving relief at 2 hours sustained for 24 to 48 hours, while a CBD-dominant product showed no clear benefit. For chronic low back pain, a phase 3 trial of a full-spectrum extract improved pain, disability, and sleep quality. The review also noted that THC-containing inhaled forms carried more psychoactive side effects.

Chronic Low Back Pain: The Phase 3 Trial That Changed the Picture

The headline result for chronic low back pain comes from a phase 3 randomized, placebo-controlled trial published in Nature Medicine in December 2025. It is the most rigorous test of a cannabis medicine for back pain to date, registered as NCT04940741.

The trial enrolled 820 adults with chronic low back pain across multiple centers. The product was not a random dispensary flower. It was VER-01, a standardized full-spectrum extract derived from Cannabis sativa DKJ127, with a composition controlled and consistent from batch to batch.

Phase A was the double-blind, placebo-controlled portion and ran for 12 weeks. The mean pain reduction was 1.9 points on the 0 to 10 numerical rating scale. The mean difference versus placebo was 0.6 points, with a 95% confidence interval of minus 0.9 to minus 0.3 and a P value below 0.001. That met the trial's primary endpoint.

The secondary results went further. On the neuropathic pain symptom inventory, participants improved by 14.4 points, a mean difference versus placebo of 7.3 points and a P value of 0.017. In the open-label Phase B, pain kept falling, reaching 2.9 points of improvement, and that gain held through Phase C. For context, our guide to CBD for back pain covers the basics.

What That Low Back Pain Result Actually Means

Here is where honesty earns its keep. A 0.6 point difference on a 0 to 10 pain scale is real, statistically solid, and modest. It is the kind of relief a person might notice on a bad day without it transforming their life. Anyone selling miracle-level back pain relief is overselling what even the best trial shows.

The trial was significant enough that the BMJ flagged it in its research highlights, a sign that the medical establishment took notice.

Side effects are part of the picture too. Adverse events were more common in the VER-01 group, reported by 83.3% of participants versus 67.3% on placebo. Most were mild to moderate and short-lived. Critically, there were no signs of dependence or withdrawal, the point people worry about most.

So the fair summary is this. A standardized full-spectrum cannabis extract produced a small but genuine improvement in chronic low back pain, along with gains in neuropathic symptoms, disability, and sleep. That is a narrow, real result, not a cure.

Migraine: Why CBD Alone Failed and THC Plus CBD Worked

Migraine tells a very different story, and it is the sharper one. A randomized, double-blind, placebo-controlled crossover trial published in Headache tested vaporized cannabis for acute migraine, treatment taken during an attack. It was published in 2026 with an online release in December 2025.

The trial treated 247 migraine attacks across 92 participants. There were four arms, each using a vaporized flower: a 6% THC flower, an 11% CBD flower, a combination with 6% THC plus 11% CBD, and a placebo.

The results separate the two cannabinoids cleanly. The THC plus CBD combination beat placebo on pain relief, reaching 67.2% versus 46.6% with an odds ratio of 2.85 and a P value of 0.016. It also beat placebo on pain freedom, hitting 34.5% versus 15.5% with a P value of 0.017, and on freedom from the most bothersome symptom, at 60.3% versus 34.5% with a P value of 0.005. Those benefits at 2 hours held out to 24 to 48 hours.

The THC-dominant flower also beat placebo for pain relief, at 68.9% versus 46.6% and a P value of 0.008, but it did not reach superiority for pain freedom at 2 hours. And then there is the finding that should end a lot of marketing claims. The CBD-dominant flower was not superior to placebo on any 2 hour endpoint. Not one. There were no serious adverse events. For more background, see our article on CBD for migraine.

The Two Hour Window and Why THC Does the Heavy Lifting

Why obsess over 2 hours? Because acute migraine treatment is judged by how fast it works. When a migraine hits, the first couple of hours decide whether the day is salvageable. A treatment that helps six hours later has already lost the race.

Read the four arms as a natural experiment. THC alone delivered relief, but it did not reliably deliver freedom at 2 hours. CBD alone did nothing measurable at that window. The combination delivered both relief and freedom, and held that gain for a day or two.

This is the clearest signal in the review. For acute migraine, it is THC that does the heavy lifting, and CBD appears to add something rather than carry the load by itself. A product marketed as pure CBD for acute migraine attacks is not backed by this evidence, and that is worth saying plainly.

It also explains a pattern from the systematic review. Inhaled, THC-containing forms carried the most psychoactive side effects. The ingredient that seems to drive the benefit is also the one that brings the intoxication and the legal complications.

What the Mouse Data Adds, and What It Cannot

Layered underneath the human trials is a small piece of mechanistic research that helps explain why the combination might work. A study in Cephalalgia, published in November 2025, looked at cannabinoids in mice. This is a mouse study, about mechanism, not human evidence.

The researchers gave mice a mixture of CBD and THC at a ratio of 100 to 1, specifically 100 mg per kg of CBD and 1 mg per kg of THC. They gave it before administering CGRP, a protein that plays a central role in migraine, directly into the brain's fluid spaces. The mixture rescued light aversion, the mouse equivalent of not being able to stand bright light during an attack, and partially rescued spontaneous pain.

Why care about a mouse? Because CGRP is the same target that modern migraine drugs like the CGRP inhibitors act on, so a CGRP mouse model is relevant to the human condition. The result hints that a CBD-heavy blend can calm a migraine-relevant pathway. But hints are not proof. Mice are not people, the doses do not map cleanly to human products, and the pre-treatment timing does not match real use during an attack. Treat this as a plausible mechanism, not a trial.

What the Real World Registry Data Adds, and Its Limits

Trials run in controlled conditions. Real life looks messier, and that is where a registry study earns its place. A 2026 analysis in Brain and Behavior drew on the UK Medical Cannabis Registry to look at migraine outcomes in 203 adult patients.

The findings were encouraging in shape. On the HIT-6 headache impact scale, the GAD-7 anxiety scale, a sleep quality scale, and the EQ-5D-5L quality of life measure, improvements held for up to 24 months, with P values below 0.010. On the MIDAS migraine disability scale, improvements held for up to 12 months, with P values below 0.050. Higher THC dose was associated with a greater likelihood of improvement on the migraine-specific measures, though the confidence intervals were wide, so read that signal with caution.

Then comes the part a registry cannot hide. About 1 in 7 patients, or 15.27%, reported adverse events, mostly mild to moderate, and three were life-threatening. The authors were clear about the biggest limitation. This is an observational registry, not a randomized trial, so it shows association and not causation. They concluded that the data offer a useful signal but that randomized controlled trials are needed to establish cause and effect.

Registry data tells you what happened to a large group of real patients over time. It cannot tell you that the cannabis caused the improvement, because people who stick with a treatment are often the ones who feel better for other reasons.

Who This Is Not For

Being honest about benefit means being honest about who should think twice. The ingredient that appears to drive the migraine benefit is THC, and THC brings baggage that CBD does not.

The first issue is psychoactivity. The systematic review found that THC-containing inhaled forms carried more psychoactive side effects than other approaches. If your goal is to stay clear-headed, drive, or work, a THC product can get in the way.

The second issue is drug testing. THC can trigger a positive test long after the acute effects fade, and that risk follows you into employment, sport, and some legal situations.

The third is legality. Access varies enormously by country and state, and a product that is legal where you live may not be legal somewhere you travel. The fourth is dependence. The back pain trial found no signs of dependence or withdrawal, which is reassuring, but that was a standardized extract under supervision, not an open-ended daily habit with high-THC products. If you have a history of substance use, talk to a clinician rather than deciding alone.

None of this is meant to scare you away, only to keep you from being surprised. If any of these describe your situation, a CBD-only path, discussed below, may be the more sensible starting place. If your pain has a neuropathic flavor, our piece on CBD for neuropathic pain covers that related picture.

If You Are CBD-Only: How to Think About Products

Plenty of people want nothing to do with THC, and that is a reasonable position. So what does the evidence say for a CBD-only approach? It says be selective and realistic.

For acute low back pain, the single 400 mg oral CBD dose was not superior to placebo. For acute migraine, the CBD-dominant flower did nothing measurable at 2 hours. Those are specific tests, so they do not rule out every CBD scenario, but they do tell you not to expect CBD to rescue an attack on demand.

Where CBD-only products still make sense is in the everyday, supportive role, especially for ongoing discomfort rather than sudden attacks. The format matters as much as the cannabinoid.

• For local, targeted aches, a topical can be applied directly where it hurts, which suits a sore lower back and the tight muscles around it. You can browse CBD topicals for targeted pain relief.
• For steady, all-day coverage with simple dosing, capsules and softgels are the easiest to keep consistent. See CBD capsules and softgels.
• For flexible dosing you can dial up or down, oils and tinctures let you fine-tune under the tongue. Explore CBD oils and tinctures.

Whichever you choose, start low, go slow, and keep a simple log of what you took and how you felt. A log turns guesswork into something you can evaluate.

Practical Steps You Can Take Now

Pull the threads together into something you can act on this week.

• Decide which job you are solving. Ongoing background ache is a different problem from an acute attack, so name your target before you buy.
• Reset your expectations for CBD. Relief, if it comes, is likely to be modest and supportive rather than dramatic. The best chronic back pain trial found a small but real effect, and CBD alone did not win its migraine test.
• Be skeptical of any product promising to stop a migraine attack with CBD alone. The strongest acute migraine evidence points to THC plus CBD, and to a lesser degree THC alone.
• If you are CBD-only, lean into topicals, capsules, and oils for daily comfort and track results honestly. If something is not helping after a fair trial, that is information, not failure.
• Treat THC as a serious choice. Weigh psychoactivity, drug testing, driving, legality, and your personal history before adding it, and involve a clinician if any of that is complicated.
• Keep your other medications in view. Cannabinoids can interact with prescription drugs, and our overview of CBD drug interactions helps you spot the ones that matter most.

Bottom Line

Cannabis is not a miracle for pain, and it is not useless either. It is specific, and specificity is exactly what the latest research delivers.

For chronic low back pain, a standardized full-spectrum extract called VER-01 produced a small but statistically solid improvement in pain, along with gains in neuropathic symptoms, disability, and sleep, in an 820-person phase 3 trial. Side effects were common but mostly mild and short-lived, with no signs of dependence or withdrawal.

For acute migraine, a vaporized combination of THC and CBD beat placebo on relief, pain freedom, and freedom from the most bothersome symptom at 2 hours, and those gains held for a day or two. THC alone helped with relief. CBD alone did nothing at that window. A mouse study offers a plausible mechanism, and a large UK registry offers an encouraging real-world signal with real limits.

The through-line from the 2026 systematic review is the one to remember. There is no class-wide effect. Results depend on the condition, the formulation, the route, and the cannabinoid mix. If you are chasing comfort with a CBD-only product, aim it at daily support rather than emergency rescue. If you are considering THC, go in with your eyes open and a clinician in the loop.

That is not a flashy message. It is a useful one, and it is the closest thing to the truth the best current evidence allows.